Key Leaders: Tien Lee, MD, Founder & CEO
Our focus was on mapping existing research, identifying trends, and discussing potential directions for further studies
Further studies in obese non-diabetic models have also identified renoprotection with GLP-1 receptor agonists (71), thus stimulating investigations into a potential clinical role for such agents in obesity-associated kidney disease in the absence of overt diabetes, as indicated below
Many users find this dose sufficient and may not need to increase further
If you or a loved one suffered a personal injury or financial loss due to a car accident in Chicago, IL you may be entitled to compensation for those damages
In addition, GLP-1 therapies appear to promote natriuresis, or increased sodium excretion, through effects on the kidneys